Work for Kodiak Sciences Inc?

Claim Your Profile

Kodiak Sciences Inc Logo Image

Kodiak Sciences Inc

Kodiak Sciences Inc Banner Image

About Kodiak Sciences Inc

11-50 Employees
Based in Palo Alto, California

Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, they are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Their ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, a leading cause of blindness in elderly patients, and diabetic eye diseases, a leading cause of blindness in working-age patients.

Ticker:
KOD
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol